192 related articles for article (PubMed ID: 24530555)
1. Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats.
Jones RB; Vickers SP; Cheetham SC; Headland KR; Mark M; Klein T
Eur J Pharmacol; 2014 Apr; 729():59-66. PubMed ID: 24530555
[TBL] [Abstract][Full Text] [Related]
2. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
Moritoh Y; Takeuchi K; Hazama M
J Pharmacol Exp Ther; 2009 May; 329(2):669-76. PubMed ID: 19208898
[TBL] [Abstract][Full Text] [Related]
3. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
Kawamori R; Inagaki N; Araki E; Watada H; Hayashi N; Horie Y; Sarashina A; Gong Y; von Eynatten M; Woerle HJ; Dugi KA
Diabetes Obes Metab; 2012 Apr; 14(4):348-57. PubMed ID: 22145698
[TBL] [Abstract][Full Text] [Related]
4. Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice.
Moritoh Y; Takeuchi K; Hazama M
Diabetes Obes Metab; 2010 Mar; 12(3):224-33. PubMed ID: 20151999
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.
Yamaguchi M; Saji T; Mita S; Kulmatycki K; He YL; Furihata K; Sekiguchi K
Int J Clin Pharmacol Ther; 2013 Aug; 51(8):641-51. PubMed ID: 23782587
[TBL] [Abstract][Full Text] [Related]
6. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
7. The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat.
Hansen HH; Hansen G; Paulsen S; Vrang N; Mark M; Jelsing J; Klein T
Eur J Pharmacol; 2014 Oct; 741():254-63. PubMed ID: 25160746
[TBL] [Abstract][Full Text] [Related]
8. Effects of linagliptin monotherapy compared with voglibose on postprandial blood glucose responses in Japanese patients with type 2 diabetes: Linagliptin Study of Effects on Postprandial blood glucose (L-STEP).
Fujitani Y; Fujimoto S; Takahashi K; Satoh H; Hirose T; Hiyoshi T; Ai M; Okada Y; Gosho M; Mita T; Watada H
Diabetes Res Clin Pract; 2016 Nov; 121():146-156. PubMed ID: 27710821
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of linagliptin and voglibose on endothelial function in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, pilot study (EFFORT).
Koyama T; Tanaka A; Yoshida H; Oyama JI; Toyoda S; Sakuma M; Inoue T; Otsuka Y; Node K
Heart Vessels; 2018 Aug; 33(8):958-964. PubMed ID: 29427024
[TBL] [Abstract][Full Text] [Related]
10. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
11. Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.
Wargent E; Stocker C; Augstein P; Heinke P; Meyer A; Hoffmann T; Subramanian A; Sennitt MV; Demuth HU; Arch JR; Cawthorne MA
Diabetes Obes Metab; 2005 Mar; 7(2):170-81. PubMed ID: 15715890
[TBL] [Abstract][Full Text] [Related]
12. Effects of linagliptin monotherapy compared with voglibose on postprandial lipid profiles in Japanese patients with type 2 diabetes: linagliptin study of effects on postprandial blood glucose (L-STEP) sub-study 1.
Kurozumi A; Okada Y; Satoh H; Inoue I; Chimori H; Akita E; Shiraiwa T; Fujitani Y; Mita T; Gosho M; Watada H
Endocr J; 2018 Apr; 65(4):415-425. PubMed ID: 29367471
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effect of long-term combined treatment with voglibose and pioglitazone on pancreatic islet function of genetically diabetic GK rats.
Ishida H; Kato S; Nishimura M; Mizuno N; Fujimoto S; Mukai E; Kajikawa M; Yamada Y; Odaka H; Ikeda H; Seino Y
Horm Metab Res; 1998 Nov; 30(11):673-8. PubMed ID: 9918384
[TBL] [Abstract][Full Text] [Related]
14. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
Barnett AH
Adv Ther; 2011 Jun; 28(6):447-59. PubMed ID: 21603986
[TBL] [Abstract][Full Text] [Related]
15. The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model.
Shang Q; Liu MK; Saumoy M; Holst JJ; Salen G; Xu G
Am J Physiol Gastrointest Liver Physiol; 2012 Apr; 302(8):G815-23. PubMed ID: 22281473
[TBL] [Abstract][Full Text] [Related]
16. The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose.
Salheen SM; Panchapakesan U; Pollock CA; Woodman OL
Pharmacol Res; 2015 Apr; 94():26-33. PubMed ID: 25697548
[TBL] [Abstract][Full Text] [Related]
17. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
[TBL] [Abstract][Full Text] [Related]
18. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).
Young AA; Gedulin BR; Bhavsar S; Bodkin N; Jodka C; Hansen B; Denaro M
Diabetes; 1999 May; 48(5):1026-34. PubMed ID: 10331407
[TBL] [Abstract][Full Text] [Related]
19. Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice.
Chen L; Klein T; Leung PS
Curr Mol Med; 2012 Sep; 12(8):995-1004. PubMed ID: 22804249
[TBL] [Abstract][Full Text] [Related]
20. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
Cuthbertson J; Patterson S; O'Harte FP; Bell PM
Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
